Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 75 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 75 versus QDOLO.
FENTANYL-75 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system, leading to decreased neurotransmitter release and hyperpolarization of neurons.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Apply 75 mcg/h transdermally every 72 hours for opioid-tolerant patients; not for acute pain. Rotate application site.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 3-12 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, or continuous infusion.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: ~75% as metabolites (primarily norfentanyl) and ~10% unchanged; fecal: ~9%; biliary: minor.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist